MRK Earnings

MRK reported its earnings on 2026-04-30, showcasing a revenue of 16.29B against an estimate of 15.90B, resulting in a 2.43% surprise. The EPS was -1.28, surpassing the expected -1.51 by 15.23%. The stock experienced a -1.6% price change on the earnings day and a 1.98% change over the next five days, reflecting market reactions to the results.

Following MRK's earnings announcement on 2026-04-30, the stock price moved by -1.6% on the day of the release. Over the subsequent five days, it saw a 1.98% change. Historically, MRK's stock price tends to shift by an average of 1.12% in the 10 days leading up to earnings and -0.08% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate MRK's annual revenue to reach 16.60B, while the EPS is projected at 2.25. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MRK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRK's stock price typically moves by 1.12% in the 10 days before its earnings and -0.08% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 2.25 and revenue of 16.60B.

The earnings call highlights strong product development, robust pipeline, and strategic focus on unmet needs, particularly in oncology and cardiometabolic diseases. Despite some unclear responses in the Q&A, the guidance remains optimistic, with significant growth drivers and potential new product launches. The anticipated strong growth in the Animal Health business and potential contributions from new products are positive indicators. The lack of a market cap suggests a moderate reaction, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.